109 related articles for article (PubMed ID: 33397152)
1. Adenosine triphosphate, polymyxin B and B16 cell-derived immunization induce anticancer response.
Barrera-Avalos C; Mena J; López X; Cappelli C; Neira T; Imarai M; Fernández R; Robles-Planells C; Rojo LE; Milla LA; Leiva-Salcedo E; Escobar A; Acuña-Castillo C
Immunotherapy; 2021 Mar; 13(4):309-326. PubMed ID: 33397152
[No Abstract] [Full Text] [Related]
2. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
3.
Barrera-Avalos C; Díaz X; Madrid B; Michelson SA; Robles-Planells C; Sánchez-Guerrero G; Ahumada V; Mella-Torres A; Rojo LE; Imarai M; Milla LA; Leiva-Salcedo E; Murgas P; Fernández R; Escobar A; Acuña-Castillo C
Biomed Res Int; 2021; 2021():6626851. PubMed ID: 33623783
[TBL] [Abstract][Full Text] [Related]
4. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
7. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
8. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
9. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
10. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
Mac Keon S; Bentivegna S; Levy EM; Marks MS; Mantegazza AR; Wainstok R; Mordoh J
Vaccine; 2019 Aug; 37(35):4947-4955. PubMed ID: 31307876
[TBL] [Abstract][Full Text] [Related]
11. Oral Administration of Polymyxin B Modulates the Activity of Lipooligosaccharide E. coli B against Lung Metastases in Murine Tumor Models.
Kicielińska J; Szczygieł A; Rossowska J; Anger N; Kempińska K; Świtalska M; Kaszowska M; Wietrzyk J; Boratyński J; Pajtasz-Piasecka E
PLoS One; 2016; 11(2):e0148156. PubMed ID: 26829479
[TBL] [Abstract][Full Text] [Related]
12. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses.
Zheng H; Liu L; Zhang H; Kan F; Wang S; Li Y; Tian H; Meng S
PLoS One; 2019; 14(1):e0211490. PubMed ID: 30703157
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.
Wang J; Wang X; Chen Y; Wan M; Xiang Z; Wu X; Wei H; Wang L; Zhang P; Wang L; Yu Y
Tumour Biol; 2013 Feb; 34(1):193-201. PubMed ID: 23055194
[TBL] [Abstract][Full Text] [Related]
16. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
17. Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma.
Yoshikawa T; Okada N; Tsujino M; Gao JQ; Hayashi A; Tsutsumi Y; Mayumi T; Yamamoto A; Nakagawa S
Biol Pharm Bull; 2006 Jan; 29(1):100-4. PubMed ID: 16394519
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue.
Mac Keon S; Gazzaniga S; Mallerman J; Bravo AI; Mordoh J; Wainstok R
Vaccine; 2010 Nov; 28(51):8162-8. PubMed ID: 20937314
[TBL] [Abstract][Full Text] [Related]
19. Covalent crosslinking of tumor antigens stimulates an antitumor immune response.
Wang Y; Wang XY; Subjeck JR; Kim HL
Vaccine; 2010 Sep; 28(40):6613-20. PubMed ID: 20682362
[TBL] [Abstract][Full Text] [Related]
20. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
